Filing Flows › Indivior Pharmaceuticals (INDV) › Q2 2026 › vs Q1 2026
Indivior Pharmaceuticals (INDV) Q2 2026 vs Q1 2026 (quarter over quarter)
Indivior Pharmaceuticals's revenue rose $26.0M (+8%) from $317M in Q1 2026 to $343M in Q2 2026. Gross margin 85.7% against 87.4% (-1.7 pts).
Indivior Pharmaceuticals, Q2 2026: revenue $343M (+14% year over year), operating margin 46.6%, net earnings $122M, operating cash flow $229M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Gross margin | 85.7% | 87.4% | -1.7 pts |
| Operating margin | 46.6% | 43.2% | +3.4 pts |
| Net margin | 35.6% | 28.1% | +7.5 pts |
| Free cash flow margin | 64.7% | -9.1% | +73.9 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $343M | $317M | $26.0M | +8% |
| Gross profit | $294M | $277M | $17.0M | +6% |
| Cost of revenue | $49.0M | $40.0M | $9.0M | +23% |
| Operating profit | $160M | $137M | $23.0M | +17% |
| Operating expenses | $134M | $140M | −$6.0M | -4% |
| Pre-tax earnings | $160M | $115M | $45.0M | +39% |
| Research & development | $12.0M | $16.0M | −$4.0M | -25% |
| SG&A | $122M | $124M | −$2.0M | -2% |
| Net earnings | $122M | $89.0M | $33.0M | +37% |
| Income tax | $38.0M | $26.0M | $12.0M | +46% |
| Depreciation & amortization | $2.0M | $2.0M | $0 | 0% |
| Share-based compensation | $11.0M | $9.0M | $2.0M | +22% |
| Working capital & other | $94.0M | −$109M | $203M | — |
| Operating cash flow | $229M | −$9.0M | $238M | — |
| Free cash flow (OCF − capex) | $222M | −$29.0M | $251M | — |
| Capital expenditures | $7.0M | $20.0M | −$13.0M | -65% |
Questions
How much did Indivior Pharmaceuticals's revenue grow quarter over quarter in Q2 2026?
Indivior Pharmaceuticals's revenue rose $26.0M (+8%) from $317M in Q1 2026 to $343M in Q2 2026. Gross margin 85.7% against 87.4% (-1.7 pts).